2025
NEW!! Dual Inhibitors of KRASG12D and HSP90 are Effective Against KRASG12D Inhibitor Resistance
Inés Pulido, Laura C Gunder, Chenghao Ying, Yaya Wang, Yan Dai, Zimo Yang, Alireza Rahnama, Jinhua Li, Yuetong Sun, Chuhe Liu, Haoxin Zhou, Guoqiang Wang , Kevin P Foley, Khaled Abdelhady, Malek G Massad, Thomas L Prince, Ian Papautsky, Weiwen Ying , Takeshi Shimamura
NEW!! NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC
Pulido I, García-Cañaveras JC, Rodríguez ML, Becker JH, López A, Aupí M, Aparisi S, Chuliá-Peris L, Tamayo-Torres E, Carreres-Rey C, Alcácer Fernández-Coronado J, Benet M, Montero S, Mena S, Sandoval J, Pereda J, Alcácer J, Calabuig S, Jantus E, Cremades A, Galbis JM, Martín-Martorell P, Insa A, Malek G. Massad, Juan-Vidal O, Lahoz A, Shimamura T, Carretero J
Chaperone directed heterobifunctional molecules circumvent KRASG12C inhibitor resistance
Ines Pulido, Qiyue Luan, Sara Pastor-Puente, Laura Gunder, Yaya Wang, Chenghao Ying, Jinhua Li, Yuetong Sun, Yan Dai, Christian Ascoli, Kahled Abdelhady, Malek Massad, Thomas Prince, Guoqiang Wang, Kevin Foley, Weiwen Ying, Ian Papautsky, Julian Carretero, Takeshi Shimamura* Cancer Letters. 2025 In Press.
2024
Deciphering fibroblast-induced drug resistance in non-small cell lung carcinoma through patient-derived organoids in agarose microwells
Luan Q, Pulido I, Isagirre A, Carretero J, Zhou J, Shimamura T, Papautsky I. Deciphering fibroblast-induced drug resistance in non-small cell lung carcinoma through patient-derived organoids in agarose microwells. Lab Chip. 2024 Mar 26;24(7):2025-2038. doi: 10.1039/d3lc01044a. PMID: 38410967.
Non-small cell lung carcinoma spheroid models in agarose microwells for drug response studies
Luan Q, Becker JH, Macaraniag C, Massad MG, Zhou J, Shimamura T, Papautsky I. Non-small cell lung carcinoma spheroid models in agarose microwells for drug response studies. Lab Chip. 2022 Jun 14;22(12):2364-2375. doi: 10.1039/d2lc00244b. PMID: 35551303; PMCID: PMC10319040.
Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma.
Pulido I, Ollosi S, Aparisi S, Becker JH, Aliena-Valero A, Benet M, Rodríguez ML, López A, Tamayo-Torres E, Chuliá-Peris L, García-Cañaveras JC, Soucheray M, Dalheim AV, Salom JB, Qiu W, Kaja S, Fernández-Coronado JA, Alandes S, Alcácer J, Al-Shahrour F, Borgia JA, Juan O, Nishimura MI, Lahoz A, Carretero J, Shimamura T. Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma. Res. 2020 Oct 1;80(19):4224-4232. doi: 10.1158/0008-5472.CAN-20-0141. Epub 2020 Aug 3. PMID: 32747363; PMCID: PMC7541638.
CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC.
Becker JH, Gao Y, Soucheray M, Pulido I, Kikuchi E, Rodríguez ML, Gandhi R, Lafuente-Sanchis A, Aupí M, Alcácer Fernández-Coronado J, Martín-Martorell P, Cremades A, Galbis-Caravajal JM, Alcácer J, Christensen CL, Simms P, Hess A, Asahina H, Kahle MP, Al-Shahrour F, Borgia JA, Lahoz A, Insa A, Juan O, Jänne PA, Wong KK, Carretero J, Shimamura T. CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC. Cancer Res. 2019 Sep 1;79(17):4439-4452. doi: 10.1158/0008-5472.CAN-19-0024. Epub 2019 Jul 4. PMID: 31273063; PMCID: PMC6746175.
Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
Soucheray M, Capelletti M, Pulido I, et al. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. Cancer Research. 2015 Oct;75(20):4372-4383. DOI: 10.1158/0008-5472.can-15-0377. PMID: 26282169; PMCID: PMC4548796.
